GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31

Grace Therapeutics, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.88−0.01 (-0.53%)

Close on Oct 19, 2026

Market cap: $32.47M
P/E (TTM): –
Dividend yield: –

Grace Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31
Cash & Equivalents	17	22	23	28	30	51	14	17
Short-Term Investments	–	–	0	0.02	13	9.79	–	8.89
Cash & Short-Term Investments	17	22	23	28	44	61	14	26
Receivables	–	–	0.72	0.80	0.55	0.53	0.55	1.19
Prepaid Expenses & Other	0.38	0.45	0.28	0.60	0.72	0.34	0.98	0.84
Other Current Assets	–	–	–	–	–	–	0.20	0.05
Total Current Assets	17	23	24	29	45	62	18	28
Property, Plant & Equipment	0.01	0.02	0.02	0.10	21	–	1.91	2.11
Gross Property, Plant & Equipment	0.02	0.03	0.72	0.71	–	–	3.10	2.96
Accumulated Depreciation	-0.01	-0.01	-0.61	-0.57	-0.45	–	-1.19	-0.85
Machinery & Equipment	0.01	0.02	0.02	0.10	0.25	–	–	–
Long-Term Investments	–	–	–	–	–	–	–	0.02
Operating Lease Right-of-Use Assets	–	–	0	0.46	0.32	0.09	0.15	–
Goodwill	8.14	8.14	8.14	8.14	13	–	–	–
Intangible Assets	41	41	41	41	70	0	4.24	6.39
Other Long-Term Assets	–	–	–	–	–	–	0.47	0.42
Total Assets	67	72	73	79	129	62	23	37
Accounts Payable	2.15	1.93	1.68	3.34	3.16	1.49	7.32	12
Accrued Expenses	–	–	0.18	0.95	0.30	0.61	4.25	7.70
Current Portion of Leases	–	–	0	0.08	0.10	0.09	0.08	–
Total Current Liabilities	2.15	1.93	1.68	3.41	3.26	1.58	7.40	14
Long-Term Leases	–	–	0	0.41	0.19	–	0.07	–
Operating Lease Liabilities	–	–	0	0.49	0.30	0.09	0.15	–
Deferred Tax Liabilities	0.61	2.31	5.51	7.35	17	–	–	–
Total Liabilities	2.76	5.38	12	11	20	6.80	9.86	26
Preferred Stock	0	0	0	–	–	–	–	–
Common Stock	0.00	0.00	0.00	258	258	197	137	111
Additional Paid-In Capital	298	293	279	14	12	11	9.80	8.15
Retained Earnings	-228	-221	-211	-198	-156	-146	-126	-101
Comprehensive Income & Other	-6.04	-6.04	-6.04	-6.04	-6.04	-6.33	-7.89	-7.14
Shareholders' Equity	64	67	62	68	108	56	13	11
Total Equity	64	67	62	68	108	56	13	11
Total Liabilities & Equity	67	72	73	79	129	62	23	37
Shares Outstanding(shares)	16	14	9.40	7.44	7.38	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -11.9%

Financial strength

Current ratio: 11.47
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1100.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.67
Dividend yield: –